BIIB — Biogen Inc.

Biogen (BIIB) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $2.5 billion, up 2% year-over-year.
• GAAP Diluted EPS: $2.15, up 31% year-over-year.
• Non-GAAP Diluted EPS: $3.57, up 18% year-over-year.
• Growth Products Revenue: $851 million, up 12% year-over-year, with LEQEMBI contributing $168 million (74% growth) and SKYCLARYS at $151 million (22% growth).
• Free Cash Flow: $594 million, with $4.7 billion in cash and marketable securities and $1.5 billion in net debt.
• Non-GAAP R&D Expense: $480 million, reflecting investments in late-stage clinical programs.

2. Strategic Updates and Business Highlights

• Business Stabilization: Following four years of declining revenue, Biogen has successfully stabilized its business, focusing on growth investments rather than cost-cutting alone.
• High-Dose SPINRAZA Launch: The new high-dose formulation has been approved and is seeing early adoption, with 20% of patients already switching to the new regimen.
• LEQEMBI Progress: Continued strong performance with nearly 80% treatment persistence at 18 months. The upcoming PDUFA date for the subcutaneous formulation is May 24.
• Acquisition of Apellis Pharmaceuticals: The proposed acquisition is expected to enhance Biogen's growth portfolio, with anticipated EPS accretion in 2027.
• Pipeline Developments: Promising data from late-stage trials, including Salanersen and Litifilimab, with multiple data readouts expected in 2026.

3. Forward Guidance and Outlook

• 2026 Guidance: Biogen maintains its revenue outlook consistent with prior guidance, expecting to incur additional IPR&D charges impacting EPS.
• Acquisition Impact: The Apellis transaction is expected to close in Q2 2026, with guidance to be updated post-closure. The deal is anticipated to enhance both top-line and bottom-line growth.
• Long-Term Growth Strategy: Biogen aims to leverage its late-stage pipeline and the Apellis acquisition to drive growth into the 2030s.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The company faces increasing competition in the ophthalmology space, particularly with other agents targeting visual acuity rather than lesion burden.
• Market Dynamics: SKYCLARYS revenue remains lumpy due to inventory dynamics, and there are challenges in patient identification and reimbursement processes.
• Regulatory Risks: The upcoming PDUFA date for LEQEMBI's subcutaneous formulation carries inherent risks regarding approval.
• Market Sentiment: Analysts expressed concerns over the sustainability of growth metrics and the need for continued innovation and execution to maintain investor confidence.

5. Notable Q&A Insights

• BIIB080 Development: The company is cautiously optimistic about the upcoming Phase II results, focusing on tau reduction as a key indicator for moving forward.
• LEQEMBI Adoption: There is a growing use of blood-based biomarkers for treatment confirmation, which may enhance patient persistence on therapy.
• SYFOVRE Competitive Landscape: Biogen is aware of evolving competition and is focused on educating physicians about SYFOVRE's benefits, particularly in lesion growth reduction.
• Future M&A Strategy: Post-Apellis, Biogen plans to focus on early-stage development and research rather than aggressive M&A, indicating a shift in strategic priorities.

This summary encapsulates the key points from Biogen's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, and areas of concern while providing insights from the Q&A session.